Corporate Governance

Opexa Therapeutics (NASDAQ:OPXA) is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The company's leading product candidate has the potential to address the significant unmet medical needs of the large multiple sclerosis (MS) patient population.

Opexa's lead therapy, Tcelna™, a cellular immunotherapy has completed a Phase 2b clinical study for the treatment of MS that is specifically tailored to each patient's disease profile. Opexa believes the potential combination of efficacy, superior safety, improved tolerability and administration may position Tcelna as the MS treatment of choice as compared to existing therapeutics.

Board of Directors Committee Listing:

Audit Committee:

  • David Jorden - Chair *
  • Scott Seaman*
  • Michael Richman

Compensation Committee:

  • Michael Richman - Chair
  • Gail Maderis
  • Scott Seaman

Governance and Nominating Committee:

  • Gail Maderis - Chair
  • Scott Seaman
  • David Jorden

*The Board has determined that Messrs. Jorden and Seaman each, individually, qualify as an "audit committee financial expert" as defined in SEC regulations and also possesses the financial sophistication and requisite experience as required under NASDAQ listing standards.

Investor Information

Corporate Governance
Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Charter
Whistleblower Policy and Code of Ethics